Total
0
Shares
Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Elixinol Global subsidiary Nunyara Pharma has been granted a license to manufacture medical cannabis
  • Nunyara can manufacture cannabis tinctures, extracts and cannabis resin
  • The company is currently waiting for its approval to receive its Medicinal Cannabis Licence

Elixinol Global subsidiary Nunyara Pharma has been granted a license to manufacture medical cannabis.

The Australian Office of Drug Control gave the license to Nunyara to manufacture cannabis tinctures, extracts and cannabis resin.

Cannabis Tinctures is also known as green or golden dragon and are alcohol based cannabis extracts, essentially infused alcohol.

A Cannabis extract is an oil-like substance that comes from the plant.

Cannabis Resin is a dark to light brown substance which is scraped off the surface of the Cannabis Plant and pressed into a solid lump.

Elixinol Global is a global leader in the cannabis industry, selling hemp-derived CBD dietary supplements, hemp food and wellness products, as well as the farming and manufacture of medicinal cannabis products.

Nunyara founded in 2014 to participate in the emerging Australian medicinal cannabis market.

The company is currently waiting for its approval to receive its Medicinal Cannabis Licence which will allow the Company to farm and produce cannabis for medicinal purposes.

Elixinol CEO, Stratos Karousos is pleased with the approval.

“The granting of the Manufacture Licence is extremely exciting and we look forward to also being granted our Medicinal Cannabis Licence shortly which will complete our licence application process for Nunyara,” he said.

EXL by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.